Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935850 | 0.78 | DPP4 (0.48) | DPP4DPP8DPP7 | |
| SCHEMBL5935844 | 0.77 | DPP4 (0.49) | DPP4DPP8DPP9GPR119 | |
| SCHEMBL16790053 | 0.74 | DPP4 (0.49) | DPP4MAPTDPP8DPP9DPP7 | |
| SCHEMBL16790034 | 0.74 | DPP4 (0.39) | DPP4DPP8DPP9GPR119 | |
| SCHEMBL16789995 | 0.74 | DPP4 (0.41) | DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL16790038 | 0.73 | DPP4 (0.38) | DPP4DPP8DPP9GPR119ALDH1A1 | |
| SCHEMBL5648690 | 0.70 | P2RX7 (0.38) | DPP4MAPTDPP8DPP9DPP7 | |
| SCHEMBL29649992 | 0.70 | DPP4 (0.42) | DPP4DPP8DPP7 | |
| SCHEMBL16790044 | 0.68 | DPP4 (0.42) | DPP4DPP8DPP9DPP7GPR119 | |
| SCHEMBL5653362 | 0.67 | DPP4 (0.49) | DPP4DPP8DPP9DPP7GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255106-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-02-09 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2881395-A1 | PIPERAZINOTRIZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | PARP1, PARP11, PARP8 | DPP4 552/4885MAPT 1182/4885DPP8 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.